## **Guy Caljon**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4727230/publications.pdf

Version: 2024-02-01

		159358	233125
142	2,988	30	45
papers	citations	h-index	g-index
150	150	150	3348
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Antiplasmodial activity of constituents and their metabolites after in vitro gastrointestinal biotransformation of a Nauclea pobeguinii extract. Phytochemistry, 2022, 194, 113029.	1.4	5
2	N-modification of 7-Deazapurine nucleoside analogues as Anti-Trypanosoma cruzi and anti-Leishmania agents: Structure-activity relationship exploration and InÂvivo evaluation. European Journal of Medicinal Chemistry, 2022, 231, 114165.	2.6	7
3	Targeting the tsetse-trypanosome interplay using genetically engineered Sodalis glossinidius. PLoS Pathogens, 2022, 18, e1010376.	2.1	1
4	The effect of the sugar metabolism on Leishmania infantum promastigotes inside the gut of Lutzomyia longipalpis: A sweet relationship?. PLoS Neglected Tropical Diseases, 2022, 16, e0010293.	1.3	2
5	Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents. European Journal of Medicinal Chemistry, 2022, 237, 114367.	2.6	4
6	Nucleoside analogues for the treatment of animal trypanosomiasis. International Journal for Parasitology: Drugs and Drug Resistance, 2022, 19, 21-30.	1.4	9
7	3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity. International Journal for Parasitology: Drugs and Drug Resistance, 2022, 19, 47-55.	1.4	5
8	Long-term hematopoietic stem cells as a parasite niche during treatment failure in visceral leishmaniasis. Communications Biology, 2022, 5, .	2.0	12
9	Synthesis and Structureâ^'Activity Relationships of Imidazopyridine/Pyrimidine―and Furopyridineâ€Based Antiâ€infective Agents against Trypanosomiases. ChemMedChem, 2021, 16, 966-975.	1.6	16
10	2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F <sub>420</sub> )-Dependent Nitroreductase (Ddn). Journal of Medicinal Chemistry, 2021, 64, 440-457.	2.9	10
11	Antimicrobial and antiprotozoal activities of silver coordination polymers derived from the asymmetric halogenated Schiff base ligands. Applied Organometallic Chemistry, 2021, 35, e6079.	1.7	11
12	Evaluation of conventional and four real-time PCR methods for the detection of Leishmania on field-collected samples in Ethiopia. PLoS Neglected Tropical Diseases, 2021, 15, e0008903.	1.3	14
13	Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine. Pharmaceuticals, 2021, 14, 196.	1.7	2
14	Tetrahydrophthalazinone Inhibitor of Phosphodiesterase with <i>In Vitro</i> Activity against Intracellular Trypanosomatids. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	1
15	Tsetse salivary glycoproteins are modified with paucimannosidic N-glycans, are recognised by C-type lectins and bind to trypanosomes. PLoS Neglected Tropical Diseases, 2021, 15, e0009071.	1.3	3
16	2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. PLoS Neglected Tropical Diseases, 2021, 15, e0009196.	1.3	8
17	Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. European Journal of Medicinal Chemistry, 2021, 212, 113101.	2.6	14
18	Antiplasmodial Oleanane Triterpenoids from <i>Terminalia albida</i> Root Bark. Journal of Natural Products, 2021, 84, 666-675.	1.5	3

#	Article	IF	CITATIONS
19	Revisiting Pyrazolo[3,4- <i>d</i> )]pyrimidine Nucleosides as Anti- <i>Trypanosoma cruzi</i> ) and Antileishmanial Agents. Journal of Medicinal Chemistry, 2021, 64, 4206-4238.	2.9	19
20	4E Interacting Protein as a Potential Novel Drug Target for Nucleoside Analogues in Trypanosoma brucei. Microorganisms, 2021, 9, 826.	1.6	8
21	Structure Activity Relationship of N-Substituted Phenyldihydropyrazolones Against Trypanosoma cruzi Amastigotes. Frontiers in Chemistry, 2021, 9, 608438.	1.8	1
22	Synthesis and evaluation of $3\hat{a}\in^2$ -fluorinated 7-deazapurine nucleosides as antikinetoplastid agents. European Journal of Medicinal Chemistry, 2021, 216, 113290.	2.6	14
23	6â∈Methylâ∈7â∈Arylâ∈7â€Deazapurine Nucleosides as Antiâ∈•Trypanosoma cruzi Agents: Structureâ∈Activity Relationship and inâ∈…vivo Efficacy. ChemMedChem, 2021, 16, 2231-2253.	1.6	10
24	Pharmacological Assessment of the Antiprotozoal Activity, Cytotoxicity and Genotoxicity of Medicinal Plants Used in the Treatment of Malaria in the Greater Mpigi Region in Uganda. Frontiers in Pharmacology, 2021, 12, 678535.	1.6	11
25	Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series. Microorganisms, 2021, 9, 1408.	1.6	8
26	Experimental Selection of Paromomycin Resistance in Leishmania donovani Amastigotes Induces Variable Genomic Polymorphisms. Microorganisms, 2021, 9, 1546.	1.6	7
27	Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition. PLoS Neglected Tropical Diseases, 2021, 15, e0009622.	1.3	12
28	Development of Novel Isoindoloneâ€Based Compounds against Trypanosoma brucei rhodesiense. ChemistryOpen, 2021, 10, 922-927.	0.9	0
29	6-Methyl-7-deazapurine nucleoside analogues as broad-spectrum antikinetoplastid agents. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 57-66.	1.4	6
30	DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 16159-16176.	2.9	31
31	7-Aryl-7-deazapurine 3′-deoxyribonucleoside derivative as a novel lead for Chagas' disease therapy: <i>iin vitro</i> i> and <i>in vivo</i> i> pharmacology. JAC-Antimicrobial Resistance, 2021, 3, dlab168.	0.9	7
32	Transmission potential of paromomycin-resistant Leishmania infantum and Leishmania donovani. Journal of Antimicrobial Chemotherapy, 2020, 75, 951-957.	1.3	11
33	C6–O-alkylated 7-deazainosine nucleoside analogues: Discovery of potent and selective anti-sleeping sickness agents. European Journal of Medicinal Chemistry, 2020, 188, 112018.	2.6	33
34	Identification of Phenylphthalazinones as a New Class of <i>Leishmania infantum</i> Inhibitors. ChemMedChem, 2020, 15, 219-227.	1.6	4
35	A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation. Scientific Reports, 2020, 10, 17268.	1.6	16
36	An Unbiased Immunization Strategy Results in the Identification of Enolase as a Potential Marker for Nanobody-Based Detection of Trypanosoma evansi. Vaccines, 2020, 8, 415.	2.1	10

#	Article	IF	CITATIONS
37	Sand Fly Studies Predict Transmission Potential of Drug-resistant Leishmania. Trends in Parasitology, 2020, 36, 785-795.	1.5	13
38	Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents. RSC Medicinal Chemistry, 2020, 11, 1267-1274.	1.7	5
39	Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
40	Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based Leishmania detection in blood as proxy for visceral burdens. Journal of Microbiological Methods, 2020, 173, 105935.	0.7	1
41	Structure–Activity Relationship Exploration of 3′-Deoxy-7-deazapurine Nucleoside Analogues as Anti- <i>Trypanosoma brucei</i> Agents. ACS Infectious Diseases, 2020, 6, 2045-2056.	1.8	20
42	Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 13, 16-21.	1.4	15
43	1-(1-Arylethylpiperidin-4-yl)thymine Analogs as Antimycobacterial TMPK Inhibitors. Molecules, 2020, 25, 2805.	1.7	4
44	A Critical Blimp-1-Dependent IL-10 Regulatory Pathway in T Cells Protects From a Lethal Pro-inflammatory Cytokine Storm During Acute Experimental Trypanosoma brucei Infection. Frontiers in Immunology, 2020, 11, 1085.	2.2	12
45	Interferon Alpha Favors Macrophage Infection by Visceral Leishmania Species Through Upregulation of Sialoadhesin Expression. Frontiers in Immunology, 2020, 11, 1113.	2.2	4
46	Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents. European Journal of Medicinal Chemistry, 2020, 201, 112450.	2.6	10
47	Feeding behavior and activity of Phlebotomus pedifer and potential reservoir hosts of Leishmania aethiopica in southwestern Ethiopia. PLoS Neglected Tropical Diseases, 2020, 14, e0007947.	1.3	13
48	Experimental Strategies to Explore Drug Action and Resistance in Kinetoplastid Parasites. Microorganisms, 2020, 8, 950.	1.6	11
49	Evaluation of a pan-Leishmania SL RNA qPCR assay for parasite detection in laboratory-reared and field-collected sand flies and reservoir hosts. Parasites and Vectors, 2020, 13, 276.	1.0	8
50	Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection. Parasites and Vectors, 2020, 13, 96.	1.0	11
51	Structural and kinetic characterization of Trypanosoma congolense pyruvate kinase. Molecular and Biochemical Parasitology, 2020, 236, 111263.	0.5	1
52	Structureâ€Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi. ChemMedChem, 2020, 15, 1310-1321.	1.6	5
53	Discovery of Diaryl Ether Substituted Tetrahydrophthalazinones as TbrPDEB1 Inhibitors Following Structure-Based Virtual Screening. Frontiers in Chemistry, 2020, 8, 608030.	1.8	5
54	In Vitro Growth Inhibition Assays of Leishmania spp Methods in Molecular Biology, 2020, 2116, 791-800.	0.4	9

#	Article	IF	CITATIONS
55	Inflammation following trypanosome infection and persistence in the skin. Current Opinion in Immunology, 2020, 66, 65-73.	2.4	10
56	Title is missing!. , 2020, 14, e0007947.		0
57	Title is missing!. , 2020, 14, e0007947.		0
58	Title is missing!. , 2020, 14, e0007947.		0
59	Title is missing!. , 2020, 14, e0007947.		0
60	Title is missing!. , 2020, 14, e0007947.		0
61	Title is missing!. , 2020, 14, e0007947.		0
62	Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2). Bioorganic and Medicinal Chemistry, 2019, 27, 4013-4029.	1.4	11
63	The synthesis and inÂvitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2019, 181, 111549.	2.6	10
64	Comparative genomic analysis of six Glossina genomes, vectors of African trypanosomes. Genome Biology, 2019, 20, 187.	3.8	71
65	Discovery of Pyrrolo[2,3- <i>b</i> )pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti- <i>Trypanosoma cruzi</i> Agents. Journal of Medicinal Chemistry, 2019, 62, 8847-8865.	2.9	21
66	Need for sustainable approaches in antileishmanial drug discovery. Parasitology Research, 2019, 118, 2743-2752.	0.6	33
67	Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 1-7.	1.4	9
68	Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 3998-4012.	1.4	13
69	Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity. Virus Research, 2019, 266, 58-68.	1.1	17
70	Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1232-1235.	1.0	6
71	Phosphonodiamidate prodrugs of N-alkoxy analogs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1051-1053.	1.0	2
72	Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae. Frontiers in Microbiology, 2019, 10, 311.	1.5	38

#	Article	IF	Citations
73	Isolation and Characterization of Clinical RSV Isolates in Belgium during the Winters of 2016–2018. Viruses, 2019, 11, 1031.	1.5	8
74	Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness. Nature Communications, 2019, 10, 5564.	5.8	49
75	In-depth comparison of cell-based methodological approaches to determine drug susceptibility of visceral Leishmania isolates. PLoS Neglected Tropical Diseases, 2019, 13, e0007885.	1.3	15
76	Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 1-7.	1.4	0
77	Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity. European Journal of Medicinal Chemistry, 2019, 164, 689-705.	2.6	40
78	Miltefosine enhances the fitness of a non-virulent drug-resistant <i>Leishmania infantum</i> strain. Journal of Antimicrobial Chemotherapy, 2019, 74, 395-406.	1.3	23
79	Amino acid based prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorganic and Medicinal Chemistry, 2019, 27, 729-747.	1.4	20
80	Evaluation of a Pan-Leishmania Spliced-Leader RNA Detection Method in Human Blood and Experimentally Infected Syrian Golden Hamsters. Journal of Molecular Diagnostics, 2018, 20, 253-263.	1.2	20
81	Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility. Journal of Antimicrobial Chemotherapy, 2018, 73, 392-394.	1.3	10
82	In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 81-86.	1.4	38
83	Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. European Journal of Medicinal Chemistry, 2018, 151, 18-26.	2.6	6
84	Evaluating drug resistance in visceral leishmaniasis: the challenges. Parasitology, 2018, 145, 453-463.	0.7	51
85	Synthesis and in vitro investigation of halogenated 1,3â€bis(4â€nitrophenyl)triazenide salts as antitubercular compounds. Chemical Biology and Drug Design, 2018, 91, 631-640.	1.5	14
86	Streptococcus pneumoniae galU gene mutation has a direct effect on biofilm growth, adherence and phagocytosis in vitro and pathogenicity in vivo. Pathogens and Disease, 2018, 76, .	0.8	19
87	Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization. Viruses, 2018, 10, 426.	1.5	12
88	The Challenges of Effective Leishmaniasis Treatment. , 2018, , 193-206.		3
89	Discovery of Novel 7-Aryl 7-Deazapurine 3′-Deoxy-ribofuranosyl Nucleosides with Potent Activity against <i>Trypanosoma cruzi</i> . Journal of Medicinal Chemistry, 2018, 61, 9287-9300.	2.9	37
90	Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents. ACS Medicinal Chemistry Letters, 2018, 9, 986-989.	1.3	20

#	Article	IF	CITATIONS
91	Neutrophils enhance early Trypanosoma brucei infection onset. Scientific Reports, 2018, 8, 11203.	1.6	33
92	Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility. Parasitology Research, 2018, 117, 3601-3612.	0.6	17
93	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
94	Novel triazine dimers with potent antitrypanosomal activity. European Journal of Medicinal Chemistry, 2018, 143, 306-319.	2.6	16
95	Comparative analysis of the internalization of the macrophage receptor sialoadhesin in human and mouse primary macrophages and cell lines. Immunobiology, 2017, 222, 797-806.	0.8	7
96	Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein. Journal of Virology, 2017, 91, .	1.5	12
97	Optimization and characterization of a murine lung infection model for the evaluation of novel therapeutics against Burkholderia cenocepacia. Journal of Microbiological Methods, 2017, 139, 181-188.	0.7	2
98	Monoclonal antibody binding to the macrophage-specific receptor sialoadhesin alters the phagocytic properties of human and mouse macrophages. Cellular Immunology, 2017, 312, 51-60.	1.4	10
99	<i>In vitro</i> â€~time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against <i>Leishmania donovani</i> and <i>Leishmania infantum</i> . Journal of Antimicrobial Chemotherapy, 2017, 72, 428-430.	1.3	21
100	Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis. Frontiers in Immunology, 2017, 8, 724.	2.2	17
101	Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage. PLoS ONE, 2017, 12, e0180532.	1.1	35
102	Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS Neglected Tropical Diseases, 2017, 11, e0005620.	1.3	28
103	Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection. Virology Journal, 2017, 14, 157.	1.4	13
104	Early Immunological Responses Upon Tsetse Fly–Mediated Trypanosome Inoculation. , 2017, , 115-132.		0
105	Molecular Basis of Drug Resistance in <i>Leishmania</i> . RSC Drug Discovery Series, 2017, , 371-386.	0.2	1
106	Tsetse Fly Saliva Proteins as Biomarkers of Vector Exposure. , 2017, , 195-208.		0
107	Tsetse fly tolerance to T. brucei infection: transcriptome analysis of trypanosome-associated changes in the tsetse fly salivary gland. BMC Genomics, 2016, 17, 971.	1.2	38
108	Immune Evasion Strategies of Trypanosoma brucei within the Mammalian Host: Progression to Pathogenicity. Frontiers in Immunology, 2016, 7, 233.	2.2	72

#	Article	IF	CITATIONS
109	Naloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded Functions. PLoS Neglected Tropical Diseases, 2016, 10, e0005234.	1.3	18
110	MIF-Mediated Hemodilution Promotes Pathogenic Anemia in Experimental African Trypanosomosis. PLoS Pathogens, 2016, 12, e1005862.	2.1	20
111	Alice in microbes' land: adaptations and counter-adaptations of vector-borne parasitic protozoa and their hosts. FEMS Microbiology Reviews, 2016, 40, 664-685.	3.9	24
112	Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis. Parasitology Research, 2016, 115, 4061-4070.	0.6	6
113	Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes. PLoS ONE, 2016, 11, e0154101.	1.1	80
114	The Dermis as a Delivery Site of Trypanosoma brucei for Tsetse Flies. PLoS Pathogens, 2016, 12, e1005744.	2.1	126
115	Paternal Transmission of a Secondary Symbiont during Mating in the Viviparous Tsetse Fly. Molecular Biology and Evolution, 2015, 32, 1977-1980.	3.5	52
116	Description of a Nanobody-based Competitive Immunoassay to Detect Tsetse Fly Exposure. PLoS Neglected Tropical Diseases, 2015, 9, e0003456.	1.3	15
117	Experimental African Trypanosome Infection by Needle Passage or Natural Tsetse Fly Challenge Thwarts the Development of Collagen-Induced Arthritis in DBA/1 Prone Mice via an Impairment of Antigen Specific B Cell Autoantibody Titers. PLoS ONE, 2015, 10, e0130431.	1.1	9
118	Delivery of a functional anti-trypanosome Nanobody in different tsetse fly tissues via a bacterial symbiont, Sodalis glossinidius. Microbial Cell Factories, 2014, 13, 156.	1.9	72
119	MIF Contributes to Trypanosoma brucei Associated Immunopathogenicity Development. PLoS Pathogens, 2014, 10, e1004414.	2.1	45
120	Serological Responses and Biomarker Evaluation in Mice and Pigs Exposed to Tsetse Fly Bites. PLoS Neglected Tropical Diseases, 2014, 8, e2911.	1.3	4
121	Genome Sequence of the Tsetse Fly ( <i>Glossina morsitans</i> ): Vector of African Trypanosomiasis. Science, 2014, 344, 380-386.	6.0	254
122	The Biology of Tsetse–Trypanosome Interactions. , 2014, , 41-59.		3
123	Options for the delivery of anti-pathogen molecules in arthropod vectors. Journal of Invertebrate Pathology, 2013, 112, S75-S82.	1.5	15
124	A Trypanosoma brucei Kinesin Heavy Chain Promotes Parasite Growth by Triggering Host Arginase Activity. PLoS Pathogens, 2013, 9, e1003731.	2.1	48
125	Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies. PLoS Neglected Tropical Diseases, 2012, 6, e1902.	1.3	15
126	Using microdialysis to analyse the passage of monovalent nanobodies through the blood–brain barrier. British Journal of Pharmacology, 2012, 165, 2341-2353.	2.7	42

#	Article	IF	CITATIONS
127	Tsetse Salivary Gland Proteins 1 and 2 Are High Affinity Nucleic Acid Binding Proteins with Residual Nuclease Activity. PLoS ONE, 2012, 7, e47233.	1.1	15
128	Expression and extracellular release of a functional anti-trypanosome Nanobody $\hat{A}^{\otimes}$ in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microbial Cell Factories, 2012, 11, 23.	1.9	65
129	Mouse models for pathogenic African trypanosomes: unravelling the immunology of host–parasite–vector interactions. Parasite Immunology, 2011, 33, 423-429.	0.7	35
130	Functional Analysis of the Twin-Arginine Translocation Pathway in Sodalis glossinidius, a Bacterial Symbiont of the Tsetse Fly. Applied and Environmental Microbiology, 2011, 77, 1132-1134.	1.4	4
131	T. brucei Infection Reduces B Lymphopoiesis in Bone Marrow and Truncates Compensatory Splenic Lymphopoiesis through Transitional B-Cell Apoptosis. PLoS Pathogens, 2011, 7, e1002089.	2.1	67
132	High Affinity Nanobodies against the Trypanosome brucei VSG Are Potent Trypanolytic Agents that Block Endocytosis. PLoS Pathogens, 2011, 7, e1002072.	2.1	58
133	Identification of a Tsetse Fly Salivary Protein with Dual Inhibitory Action on Human Platelet Aggregation. PLoS ONE, 2010, 5, e9671.	1.1	46
134	The Central Role of Macrophages in Trypanosomiasis-Associated Anemia:Rationale for Therapeutical Approaches. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 71-82.	0.6	40
135	Trypanosoma brucei Modifies the Tsetse Salivary Composition, Altering the Fly Feeding Behavior That Favors Parasite Transmission. PLoS Pathogens, 2010, 6, e1000926.	2.1	91
136	Current status of vaccination against African trypanosomiasis. Parasitology, 2010, 137, 2017-2027.	0.7	46
137	Identification of a functional Antigen5-related allergen in the saliva of a blood feeding insect, the tsetse fly. Insect Biochemistry and Molecular Biology, 2009, 39, 332-341.	1.2	36
138	The Glossina morsitans tsetse fly saliva: General characteristics and identification of novel salivary proteins. Insect Biochemistry and Molecular Biology, 2007, 37, 1075-1085.	1.2	33
139	Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies that are a useful tool for exposure assessment. International Journal for Parasitology, 2006, 36, 1025-1035.	1.3	50
140	Tsetse Fly Saliva Accelerates the Onset of Trypanosoma brucei Infection in a Mouse Model Associated with a Reduced Host Inflammatory Response. Infection and Immunity, 2006, 74, 6324-6330.	1.0	58
141	Control of Experimental Trypanosoma brucei Infections Occurs Independently of Lymphotoxin-α Induction. Infection and Immunity, 2002, 70, 1342-1351.	1.0	33
142	Open Synthesis Network Research in an Undergraduate Laboratory: Development of Benzoxazole Amide Derivatives against <i>Leishmania</i> Parasite. Journal of Chemical Education, 0, , .	1,1	3